#United States #New York #The Gross Law Firm #Pacira BioSciences #PCRX

Attention Pacira BioSciences Shareholders!

In a significant development for investors, a securities fraud class action lawsuit is currently pending against Pacira BioSciences, Inc. (NASDAQ: PCRX). The Gross Law Firm has issued a crucial notice for shareholders who acquired shares during the class period from August 2, 2023, to August 8, 2024. This announcement highlights a pressing deadline for shareholders, which is March 14, 2025, to discuss their rights and the potential for recovery.

The Allegations

According to the complaint, on August 9, 2024, Pacira released a disconcerting statement regarding its lawsuit against the company eVenus concerning patent infringement. The court ruled that Pacira’s U.S. Patent No. 11,033,495—critical to their Exparel product—was deemed invalid. This ruling is particularly alarming since Exparel has been a significant source of revenue for Pacira, accounting for approximately 80% of the company's income. The analysts have indicated that the invalidation of this key patent raises serious questions about the legitimacy of other patents held by Pacira, which could lead to a surge in generic versions of their drugs entering the market, coupled with heightened litigation expenses.

Following the announcement, Pacira's stock experienced a staggering decline. From a closing price of $22.36 on August 8, 2024, the shares plummeted to a low of $11.70 on August 9, marking a colossal drop of over 47% in just 24 hours.

What’s Next for Shareholders?

The Gross Law Firm encourages all shareholders who purchased shares during the specified timeframe to register without delay. By registering, shareholders will be enrolled in a portfolio monitoring program, providing updates throughout the case's lifecycle. It is essential that shareholders understand that they do not need to be appointed as a lead plaintiff to participate in any potential recovery.

Moreover, there are no costs or obligations for shareholders who wish to join this case. As part of this initiative, you will be privy to developments and can stay informed on the actions taken throughout the class action process.

Why Choose The Gross Law Firm?

The Gross Law Firm is renowned for its commitment to protecting the rights of investors who have suffered losses due to deceitful business practices and illegal activities by corporations. Their mission is to ensure that all companies observe ethical business practices and engage in responsible corporate behavior. By collaborating with The Gross Law Firm, investors take a proactive step in ensuring that their interests are defended against misleading statements and actions by the companies in which they invest.

Contact Information

To discuss your rights and to register as a shareholder who purchased PCRX shares during the class period, please connect with:

• - The Gross Law Firm

15 West 38th Street, 12th Floor
New York, NY 10018
Phone: (646) 453-8903
Email: [email protected]

Shareholders are strongly urged to act quickly and secure their positions before the upcoming deadline of March 14, 2025. Your investment rights may depend on it!